drugset / Trial / NCT05790239

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

NCT05790239

Phase 2 Recruiting 40 enrolled Stephen Robert Marder
RandomizedParallel-groupTriple-blindTreatment

Summary

This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.

Timeline

Start
2025-03-01
Primary completion
2026-03
Completion
2026-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dextroamphetamine Small molecule 5 mg
Comparator Dextroamphetamine Small molecule 10 mg
Subject Midomafetamine Unknown 68 mg
Subject Midomafetamine Unknown 100 mg